Related Experiment Videos
Coronary revascularization on balance: Robert L. Frye lecture
Katherine M Detre1, Richard Holubkov
1Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, PA 15261, USA. detre@edc.gsph.pitt.edu
Mayo Clinic Proceedings
|January 17, 2002
Summary
Coronary artery bypass surgery and percutaneous coronary intervention (PCI) offer survival benefits for specific heart conditions. Randomized trials guide evidence-based cardiovascular treatments, contributing significantly to reduced mortality.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Clinical Trials
Background:
- Early trials (1970s) established coronary artery bypass surgery (CABS) benefits for left main disease and high-risk patients.
- Percutaneous coronary intervention (PCI) emerged later, with trials comparing it to medical therapy in stable and unstable angina.
- PCI demonstrated superiority over lytic therapy in acute myocardial infarction and cardiogenic shock in high-volume centers.
Discussion:
- CABAS vs. PCI trials showed no overall survival difference, except CABAS prolonged life in diabetic patients.
- Revascularization did not affect myocardial infarction incidence, but bypass grafts mitigated fatal outcomes.
- All revascularization trials reported improved quality of life compared to less aggressive treatments.
Key Insights:
- Randomized controlled trials (RCTs) are crucial for evidence-based cardiovascular practice.
- Interventional treatments have contributed more to cardiovascular mortality decline than primary prevention.
- RCTs provide biological insights and data for population health modeling.
Outlook:
- Continued research through RCTs is essential for advancing medical therapeutics.
- Understanding treatment impacts informs public health strategies and guidelines.
- Future research should focus on refining revascularization techniques and patient selection.